This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Stephanie B. Seminara, MD, Massachusetts General Hospital
Information provided by (Responsible Party):
Stephanie B. Seminara, MD, Massachusetts General Hospital Identifier:
First received: August 24, 2011
Last updated: June 16, 2017
Last verified: June 2017

The investigators are looking for subjects to complete a study on the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that tells the body to produce other reproductive hormones. However, giving someone a continued amount of kisspeptin over a period of time can have the opposite effect and tell the body to, for a short time, stop making hormones needed for reproduction. By giving 24-hour infusions of kisspeptin, the investigators hope to learn more about the role kisspeptin has in the way bodies function normally and the role it has in conditions that affect the reproductive system.

The investigators are initially seeking healthy men, healthy women with regular menstrual cycles, and healthy postmenopausal women. In a later part of the study, the investigators will also enroll subjects with reproductive disorders. Study participation involves 2 outpatient visits and one 38-hour hospital admission when subjects will receive kisspeptin and Gonadotropin releasing hormone (GnRH).

Individuals interested in learning more may call 617-724-8764.

Condition Intervention Phase
Hypogonadotropic Hypogonadism Healthy Postmenopausal Women Primary Gonadal Insufficiency in Men Hypergonadotropic Hypogonadism in Men Klinefelter Syndrome Drug: kisspeptin 112-121 Drug: GnRH Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

Resource links provided by NLM:

Further study details as provided by Stephanie B. Seminara, MD, Massachusetts General Hospital:

Primary Outcome Measures:
  • Luteinizing hormone (LH) level [ Time Frame: 6 hours ]

Secondary Outcome Measures:
  • Follicle stimulating hormone (FSH) levels [ Time Frame: 6 hours ]
  • testosterone (males) [ Time Frame: 6 hours ]
  • estradiol (females) [ Time Frame: 6 hours ]
  • Complete blood count (CBC) [ Time Frame: 1 month ]
  • Blood urea nitrogen (BUN) [ Time Frame: 1 month ]
  • creatinine [ Time Frame: 1 month ]
  • liver function studies [ Time Frame: 1 month ]

Estimated Enrollment: 156
Actual Study Start Date: September 2011
Estimated Study Completion Date: September 2019
Estimated Primary Completion Date: September 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: kisspeptin, GnRH
24-hour continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg), and single bolus of GnRH (gonadotropin-releasing hormone) (2.5-250 ng/kg)
Drug: kisspeptin 112-121
24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
Other Name: metastin 45-54
Drug: GnRH
Single intravenous dose of GnRH (2.5-250 ng/kg)
Other Name: gonadotropin-releasing hormone

Detailed Description:
Please contact study staff for a detailed description.

Ages Eligible for Study:   21 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • age 21-40 years (healthy men and regularly cycling women) OR age 48-60 years (healthy postmenopausal women)
  • history of normal puberty with respect to onset and pace
  • body mass index (BMI) 18.5-35 kg/m2; -systolic blood pressure <140 mm Hg, diastolic blood pressure <90 mm Hg
  • white blood cell count (WBC), platelets, prolactin, and thyroid stimulating hormone (TSH) within 90%-110% of laboratory reference range
  • hemoglobin:

    1. For men and postmenopausal women: normal
    2. For cycling women not in follicular phase: within normal reference range
    3. For cycling women in follicular phase: no lower than 1 gm/dL below the lower limit of the reference range, as they may have slightly lower levels due to menstruation
  • blood urea nitrogen (BUN), creatinine, liver function tests not elevated
  • normal luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone (men), estradiol (women)
  • for cycling women, regular menstrual cycles 25-35 days in duration
  • for postmenopausal women, no menstrual periods within the last year and a history of regular menstrual cycles
  • for all women, negative serum human chorionic gonadotropin (hCG) pregnancy test at the time of screening and negative urine hCG pregnancy test at the time of drug administration
  • for men, normal erectile and ejaculatory function by report, and no history of reproductive disorders (e.g., cryptorchidism)
  • for men, testicular volume 15 mL or greater by Prader orchidometer

Exclusion Criteria:

  • use of prescription medications in prior 2 months (with the exception of seasonal allergy medications, certain psychotropic medications, levothyroxine for hypothyroidism, albuterol for asthma, statins for dyslipidemia for all or hormone replacement therapy for postmenopausal women)
  • illicit drug use
  • consumption of more than 10 alcoholic drinks per week
  • history of anaphylactic reactions
  • history of chronic disease
  • difficulty with blood draws
  • for cycling women, use of hormonal therapy in prior 2 months
  • for women, lack of access of non-hormonal contraception if sexually active with a male partner
  • for women, evidence of androgen excess (e.g., hirsutism or acne)
  • for women, breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01438073

Contact: Addie Davies 617-724-8764
Contact: Margaret Lippincott, M.D. 617-726-8434

United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator: Stephanie B Seminara, MD         
Sub-Investigator: Yee-Ming Chan, MD, PhD         
Sub-Investigator: Margaret Lippincott, MD         
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Stephanie B Seminara, MD Massachusetts General Hospital
  More Information

Responsible Party: Stephanie B. Seminara, MD, Associate in Medicine, Massachusetts General Hospital Identifier: NCT01438073     History of Changes
Obsolete Identifiers: NCT01862094
Other Study ID Numbers: 2011-P-001564
Study First Received: August 24, 2011
Last Updated: June 16, 2017

Additional relevant MeSH terms:
Klinefelter Syndrome
Gonadal Disorders
Endocrine System Diseases
Sex Chromosome Disorders of Sex Development
Disorders of Sex Development
Urogenital Abnormalities
Sex Chromosome Disorders
Chromosome Disorders
Congenital Abnormalities
Genetic Diseases, Inborn
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 21, 2017